Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
Morgan Stanley Maintains Equal-Weight on Acadia Pharmaceuticals, Lowers Price Target to $24
Acadia Pharmaceuticals Fell While Sales Rose
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
Acadia Pharmaceuticals (ACAD) Stock Still Looks Like A Bargain Today
Acadia Pharmaceuticals (ACAD) Cuts 2026 R And D Guidance, Is It Still 46% Undervalued?
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
Acadia Pharmaceuticals Inc. 2026 Q3 - Results - Earnings Call Presentation
Canaccord Genuity Maintains Buy on Acadia Pharmaceuticals, Raises Price Target to $38
Acadia Pharmaceuticals Sees Continued Daybue Momentum in Q3, RBC Says
RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38
ACADIA Pharmaceuticals Inc (ACAD) Q3 2026 Earnings Call Highlights: Record Debut Sales and ...
Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call
Acadia: Q3 Earnings Snapshot
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
ACADIA Pharmaceuticals Q3 2026 Earnings Call Transcript
ACADIA Pharmaceuticals Narrows FY2026 Sales Guidance from $1.240B-$1.300B to $1.265B-$1.295B vs $1.272B Est
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.